Akeso

CompanyChina

Akeso develops 2 assets, the furthest in phase 3 (AK112 in biliary tract cancer). Mostly antibody acting on PDCD1 and VEGFA; based in China.

Assets
2
Furthest
Phase 3
Trials
7
Signals
0

Pipeline

2

  • AK112

    Bispecific antibody targeting PD-1 and VEGF

    Phase 3AntibodyVEGFAPDCD1biliary tract cancercervical cancer

  • Penpulimab

    Monoclonal antibody targeting PD-1

    Phase 3AntibodyPDCD1biliary tract cancercervical cancer

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms3
  • Trials9
  • Similar companies6

Updated 7 Oct 2026 · 22 sources

Intelligence